Literature DB >> 11472422

Co-incubation of pig islet cells with spleen cells from non-obese diabetic mice causes decreased insulin release by non-T-cell- and T-cell-mediated mechanisms.

S You1, A S Rivereau, E Gouin, P Saï.   

Abstract

In vitro studies were conducted in the non-obese diabetic (NOD) mouse, prone to Type 1 autoimmune diabetes, to investigate the mechanisms involved in cell-mediated rejection of pig islet xenografts. Our previous work concerning the mechanisms of proliferation of xenogeneic lymphocytes to pig islet cells (PIC) was not indicative of PIC impairment. Consequently, a test was developed based on perifusion analysis of the alteration of basal and stimulated insulin release from adult PIC incubated with mouse splenocytes or subsets. Compared with PIC incubation alone or with syngeneic pig splenocytes, co-incubation with mouse whole spleen cells resulted in a decrease of basal and stimulated insulin release (P < 0.001). Two components of this alteration were detected separately: PIC impairment was decreased (P < 0.01) after removal of plastic-adherent cells from spleen cells, but maintained (P < 0.01) when plastic-adherent cells alone were co-incubated with PIC. The increase of murine interleukin-1 beta when mouse plastic-adherent spleen cells were cultured with PIC (P < 0.04) was indicative of macrophage activation. Soluble factors produced during co-incubation of mouse splenocytes or plastic-adherent cells with PIC were involved in the impairment process, since supernatant fluids collected during previous PIC-mouse cell co-incubations directly altered (P < 0.01) insulin release from PIC. Moreover, impairment of PIC by mouse spleen cells was abolished (P < 0.01) by gadolinium chloride (which inhibits macrophages), but not by cyclosporin A. Another mechanism was apparent, since co-incubation of PIC with purified mouse T cells or CD4+ T cells, re-mixed with antigen-presenting cells, led to a decrease (P < 0.01) of insulin release. This model, based on the alteration of dynamic basal and stimulated insulin release, is indicative of in vitro cell-mediated alteration of PIC in the NOD mouse. The effect of whole spleen cells was rapid, and a crucial role was played by plastic-adherent cells. Two mechanisms were responsible for the behaviour of these cells: an early direct effect (at least in part via soluble products); and the indirect presentation of PIC xenoantigens (leading to impairment by CD4+ T lymphocytes).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11472422      PMCID: PMC1906101          DOI: 10.1046/j.1365-2249.2001.01572.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  14 in total

1.  Effect of GK1.5 monoclonal antibody dosage on survival of pig proislet xenografts in CD4+ T cell-depleted mice.

Authors:  C J Simeonovic; R Ceredig; J D Wilson
Journal:  Transplantation       Date:  1990-05       Impact factor: 4.939

2.  Primary nonfunction of islet xenografts in rat recipients results from non-T-cell-mediated immune responses.

Authors:  S Deng; R J Ketchum; T Kucher; M Weber; A Naji; K L Brayman
Journal:  Transplant Proc       Date:  1997-05       Impact factor: 1.066

3.  Intensity and mechanisms of in vitro xenorecognition of adult pig pancreatic islet cells by CD4+ and CD8+ lymphocytes from type I diabetic or healthy subjects.

Authors:  S Lalain; L Chaillous; E Gouin; P Saï
Journal:  Diabetologia       Date:  1999-03       Impact factor: 10.122

4.  Toxic effects of superoxide, hydrogen peroxide, and nitric oxide on human and pig islets.

Authors:  H Jahr; R G Bretzel; T Wacker; S Weinand; H Brandhorst; D Brandhorst; D Lau; B J Hering; K Federlin
Journal:  Transplant Proc       Date:  1995-12       Impact factor: 1.066

5.  Macrophages and nitric oxide are involved in primary nonfunction of islet xenografts.

Authors:  R L Marquet; F Bonthuis; S Y Duval; R W de Bruin; N van Rooijen; M Scheringa; J N IJzermans
Journal:  Transplant Proc       Date:  1995-02       Impact factor: 1.066

6.  Gadolinium chloride-induced macrophage blockade prevents rejection of human insulinoma cell xenograft in rats.

Authors:  G Lázár; G Farkas; J Csanádi; G Lázár
Journal:  Transplantation       Date:  1997-03-15       Impact factor: 4.939

7.  Transplantation of porcine fetal pancreas to diabetic patients.

Authors:  C G Groth; O Korsgren; A Tibell; J Tollemar; E Möller; J Bolinder; J Ostman; F P Reinholt; C Hellerström; A Andersson
Journal:  Lancet       Date:  1994-11-19       Impact factor: 79.321

8.  Primary nonfunction of islet grafts in autoimmune diabetic nonobese diabetic mice is prevented by treatment with interleukin-4 and interleukin-10.

Authors:  A Faust; H Rothe; U Schade; E Lampeter; H Kolb
Journal:  Transplantation       Date:  1996-09-15       Impact factor: 4.939

9.  A comparison of organ cultured fetal pancreas allo-, iso-, and xenografts (pig) in non-immunosuppressed non-obese diabetic mice.

Authors:  T E Mandel; J Kovarik; M Koulmanda
Journal:  Am J Pathol       Date:  1995-09       Impact factor: 4.307

10.  Differential roles of Mac-1+ cells, and CD4+ and CD8+ T lymphocytes in primary nonfunction and classic rejection of islet allografts.

Authors:  D B Kaufman; J L Platt; F L Rabe; D L Dunn; F H Bach; D E Sutherland
Journal:  J Exp Med       Date:  1990-07-01       Impact factor: 14.307

View more
  2 in total

1.  Rapid functional evaluation of beta-cells by extracellular recording of membrane potential oscillations with microelectrode arrays.

Authors:  Thomas Pfeiffer; Udo Kraushaar; Martina Düfer; Sven Schönecker; Dirk Haspel; Elke Günther; Gisela Drews; Peter Krippeit-Drews
Journal:  Pflugers Arch       Date:  2011-09-24       Impact factor: 3.657

2.  Normal Insulin Secretion from Immune-Protected Islets of Langerhans by PEGylation and Encapsulation in the Alginate-Chitosan-PEG.

Authors:  Nahid Najafikhah; Sameereh Hashemi-Najafabadi; Saleh Zahediasl; Mohammad Mahdi Nabavimanesh; Khadijeh Farrokhfall
Journal:  Iran J Biotechnol       Date:  2018-12-12       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.